Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer
Status:
Completed
Trial end date:
2015-02-23
Target enrollment:
Participant gender:
Summary
This is a Phase I/Ib, open-label, multicenter, dose-escalation trial of paclitaxel in
combination with defactinib (VS-6063), a focal adhesion kinase inhibitor, in patients with
advanced ovarian cancer. This clinical study is comprised of 2 parts: Phase I (Dose
Escalation) and Phase Ib (Expansion). The purpose of this study is to assess assess the
safety (including the recommended phase 2 dose), the pharmacokinetics, and the anti-cancer
activity of defactinib (VS-6063) when administered in combination with paclitaxel.
Pharmacodynamic effects will also be examined in tumor biopsies.